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Background: It has been proposed that the chemokine receptor,
CXCR4, and its ligand, stromal cell-derived factor-1 (SDF-1), play
a critical role in organ-specific tumor metastasis. High CXCR4
expression in resected non-small cell lung cancer (NSCLC) tumors
is associated with poorer outcome; however, its effect on patient
outcome in advanced NSCLC has not been explored.
Methods: After institutional ethical approval was obtained, demo-
graphic details, clinical variables, and outcome data were collected
on consecutive NSCLC patients diagnosed at the Tom Baker Cancer
Centre from 2003 to 2006 (Glans-Look Lung Cancer Database).
Formalin-fixed paraffin-embedded diagnostic biopsies from stage IV
patients were obtained and tissue microarrays generated. CXCR4
expression within NSCLC cells was analyzed by quantitative fluo-
rescent immunohistochemistry using the HistoRx PM-2000 platform
and then correlated with clinical outcome.
Results: Of 832 patients, 170 had samples suitable for tissue
microarray generation and analysis. Automated immunohistochem-
istry for CXCR4 was successfully completed on all 170 patients.
High expressors had a significantly poorer median overall survival
of 2.7 months versus 5.6 months for the low expressors (p 
0.0468). This difference is driven by high-expressing females who
have a median overall survival of 1.6 months versus 6.4 months for
the low expressors (p  0.006).
Conclusions: CXCR4 is expressed in the majority of NSCLC
tumors, and overexpression is associated with significantly poorer
survival in stage IV NSCLC patients. Interestingly, this poor out-
come is disproportionately represented in the female population. Our
results suggest a gender-dependent difference in clinical outcome
based on CXCR4 overexpression in stage IV NSCLC.
Key Words: CXCR4, Non-small cell lung cancer, Outcome, Fe-
males, Stage IV.
(J Thorac Oncol. 2011;6: 1169–1178)
Lung cancer is the leading cause of death from cancerworldwide; however, despite extensive research, only
small incremental outcome improvements have been realized.
Metastatic spread constitutes the primary source of morbidity
and mortality in all cancers, and dissemination to lung, liver,
bone, and brain is characteristic of non-small cell lung cancer
(NSCLC). The majority of patients present with advanced or
metastatic disease, and consequently overall 5-year survival
is a disappointing 15%. The use of platinum-based doublet
chemotherapy has pushed median overall survival in the
metastatic setting from 4 to 6 months to 8 to 10 months,1,2 but
even with the advent of targeted therapy, metastatic NSCLC
remains incurable.3,4 Just as discouraging is the high rate of
distant recurrence for resected stage I and II disease, despite
adjuvant treatment.5,6 Clearly, a thorough understanding of
the metastatic process is crucial to developing effective new
therapies for lung cancer.
A growing appreciation of the role of chemokines in
cancer has generated insight into molecular pathways that
may drive invasion and metastasis. Chemokines, a class of
small (8–14 kDa) proinflammatory chemotactic cytokines,7
play a predominant role in regulating the homing and traf-
ficking of various leukocyte subpopulations, particularly dur-
ing inflammation, tissue damage, and infection.8,9 The stro-
mal cell-derived factor (SDF-1)/CXCR4, chemokine/receptor
axis, has attracted particular interest in this context. This
chemokine/receptor axis normally plays a critical role in the
homing and retention of hematopoietic stem cells and
lymphocytes in the bone marrow10,11 and the trafficking of
these cells to sites of tissue inflammation and damage. It
has been noted that the metastasis of tumor cells shares
many similarities with the normal trafficking of hemato-
poietic stem cells, and CXCR4 activation can induce
cytoskeletal rearrangement, adhesion to endothelial cells,
polarized migration of cells to specific organs, and the
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secretion of angiopoietic factors,12–15 all important com-
ponents of the metastatic process.
Preclinical and clinical studies support the suggestion
that the CXCR4/SDF-1 axis plays a role in the metastasis of
many types of tumors including breast,16–19 ovarian,20 colo-
rectal,21 head and neck,22,23 and pancreatic carcinomas,24,25
among others. Increasing evidence also suggests that the
CXCR4/SDF-1 chemokine axis plays a pivotal role in the
metastasis of lung cancer, particularly in NSCLC. It has been
shown that many NSCLC cell lines express high levels of
CXCR4 and that SDF-1-activated CXCR4 promotes migra-
tion and invasion of these cell lines in vitro.26,27 In addition,
preferential sites of lung cancer metastases in vivo have
significantly higher levels of SDF-1 protein expression than
the primary tumor or plasma levels, suggesting that a che-
motactic gradient may be established between the site of the
primary tumor and metastatic sites. Furthermore, neutraliza-
tion of the CXCR4/SDF-1 axis is associated with a decrease
in NSCLC metastases to several organs, including the adrenal
glands, liver, lung, brain, and bone marrow in vivo.28
Importantly, several retrospective studies in stage I
and II patients have also examined the role of CXCR4 in
NSCLC by investigating the association between CXCR4
expression and clinical outcome. Spano et al. assessed the
expression of CXCR4, by semiquantitative immunohisto-
chemistry (IHC), in NSCLC tumors resected from patients
with stage I disease. They found that CXCR4 was present
in the cytoplasm of the tumor cells of all tissue specimens
tested but was absent in normal lung tissue. They also
found that there was strong nuclear staining in a significant
number of tumor specimens and a positive correlation was
seen between CXCR4 nuclear expression and better prog-
nosis, but no association between cytoplasmic CXCR4
expression and outcome was seen.29
Minamiya et al.30 reported that high CXCR4 expres-
sion, as assessed by semiquantitative real-time reverse tran-
scription PCR, was associated with a better clinical outcome
and longer 5-year disease-free survival in early-stage resected
patients with adenocarcinoma tumor histology. Similarly,
Wagner et al.31 demonstrated that nuclear CXCR4 expression
conferred a survival benefit in patients with adenocarcinoma
and also found that high cytomembranous CXCR4 expression
was an independent prognostic marker of worse survival. In
contrast, other studies have demonstrated that high nuclear
staining of CXCR4 was associated with lymph node metas-
tasis,32 and both cytoplasmic and nuclear staining was an
indicator of a worse prognosis.33
On this basis, it can be suggested that the CXCR4/
SDF-1 axis plays an important yet incompletely defined role
in the development and metastasis of NSCLC. Although there
seems to be a somewhat established role for CXCR4 in the
metastasis of early-stage NSCLC, the impact of CXCR4
expression on outcome of stage IV NSCLC patients has not
been explored. Herein, we describe investigations to deter-
mine whether CXCR4 is an independent prognostic bio-
marker of overall survival in NSCLC patients with advanced
stage IV disease by quantitative fluorescent immunohisto-
chemical analysis of ex vivo tumor samples.
MATERIALS AND METHODS
Case Selection and Clinical Data Collection
This study was approved by the University of Calgary
Conjoint Faculties Research Ethics Board, in accordance with
the Tri-Council Policy Statement on Research with Human
Subjects. Clinical data were collected retrospectively through
chart review of NSCLC patients diagnosed at the Tom Baker
Cancer Centre (TBCC) from 2003 to 2006 and entered into
the Glans-Look Lung Cancer Database. All patients diag-
nosed during this period as identified by the provincially
legislated Alberta Cancer Registry were included. Relevant
data were obtained from physician progress notes, pathology
reports, diagnostic imaging reports, laboratory results, and
other hospital records. Demographic details included age at
diagnosis, gender, birthplace, and smoking status; clinical
variables included stage of disease, tumor histology, treat-
ment modalities, and outcome data.
Staging was performed according to the American Joint
Committee on Cancer tumor, node, metastasis system and
reflected the recent 2009 revisions for NSCLC staging. In the
new system, patients designated M1a had metastases con-
tained to the thorax (including contralateral lung and malig-
nant pleural effusions), while those patients designated M1b
had distant metastases outside of the thorax (bone, brain,
viscera, and skin/subcutaneous). Data on actual patient eth-
nicity were unavailable, so patient origin was used as a
surrogate for ethnicity and was determined by the birthplace
of the patient. North American origin included patients born
in both Canada and the United States. Southeast Asian origin
included patients born in China, Japan, Cambodia, Philip-
pines, Indonesia, Korea, Malaysia, and Vietnam. Origin clas-
sified as “other” included patients born in Africa, Europe,
South America, Australia, South and West Asia, and un-
known birthplaces. Smoking status was determined by the
attending physician: nonsmoking status was defined as hav-
ing smoked less than 100 cigarettes total, while a current
smoking status was assigned if the patient smoked at the time
of diagnosis. Rural or urban status was determined based on
the patient’s residential postal code at the time of diagnosis.
Tumor histology was determined by a pathologist when
adequate tissue was available. Those patients whose tumors
were designated “histology not otherwise specified (NOS)”
included those patients where a specific histological diagnosis
could not be made from the available tissue and those without
a pathological tissue diagnosis.
Tissue Microarray Generation
All archived formalin-fixed paraffin-embedded tumor
samples from stage IV NSCLC patients included in the
clinical database were retrieved from Calgary Laboratory
Services. Hematoxylin and eosin-stained slides were re-
viewed by a pathologist to confirm diagnosis, and those
deemed to be of sufficient quality were selected and marked
for sampling and inclusion into the tissue microarray
(TMA). Representative cores (0.6 mm) from each speci-
men were assembled in triplicate (when adequate material
was available) into each TMA (25–45 specimens per
TMA) using a Beecher Manual Tissue Microarrayer
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(Beecher Instruments Inc., Sun Prairie, WI). Normal lung
tissue specimens, normal tonsil tissue, and Hela cells were
also included as controls.
Fluorescent Immunohistochemical Staining
After TMA construction, 5-m-thick sections were cut
from the TMA block and deparaffinized in xylene, rinsed in
ethanol, and rehydrated. Heat-induced epitope retrieval was
performed by heating slides to 121°C in a citrate-based buffer
(pH 6.0) Target Retrieval Solution (Dako, Mississauga, ON,
Canada) for 3 minutes in a decloaking chamber (Biocare
Medical, Concord, CA). Endogenous peroxidase activity was
quenched with a 10-minute incubation of peroxidase block
(Dako) followed by a 15-minute protein block (Signal Stain,
Cell Signaling, Danvers, MA) to eliminate nonspecific anti-
body binding. Slides were stained overnight in a humidified
chamber at room temperature with Signal Stain protein block
(Cell Signaling) with a 1:500 dilution of anti-pan-cytokeratin
mouse monoclonal antibody (Dako) to identify tumor cells,
combined with a 1:25 dilution of anti-CXCR4 rabbit mAb
(clone UMB2, Biotrend, Ko¨ln, Germany).34 The following
day, slides were washed with tris-buffered saline and tween
20 (TBST) wash buffer (Dako), and corresponding secondary
antibodies were applied for 60 minutes at room temperature:
goat anti-mouse antibody conjugated to a horseradish perox-
idase-decorated dextran polymer backbone from the DAKO
EnVision system (Dako) and a 1:200 dilution of Alexa-
555-conjugated goat anti-mouse antibody (Invitrogen, Burl-
ington, ON, Canada). The slides were washed with TBST
wash buffer (Dako) and incubated for 5 minutes with the
TSA-Plus Cy5 tyramide signal amplification reagent
(PerkinElmer, Woodbridge, ON, Canada). After three washes
in TBST wash buffer, the TMA slides were mounted with
ProLong Gold antifade mounting medium containing DAPI
(Invitrogen) and stored at 4°C until use.
Automated Image Acquisition and Analysis
Automated image acquisition was performed using the
HistoRx PM-2000, which has previously been described in
detail.35 Briefly, high-resolution monochromatic 8-bit digital
images (resulting in 256 discrete intensity values per pixel of
an acquired image) were obtained for every histospot on the
TMAs using filters specific for DAPI to define the nuclear
compartment, Cy3 to define cytokeratin-positive NSCLC
cells and the tumor cytosolic compartment, and Cy5 to define
the target biomarker CXCR4. Pixels were then written to
image files as a function of power (Power [P]  [Pixel
Intensity/256]/exposure time) to help compensate for exper-
imental variations in staining intensity.
Images were taken for each channel for future use with
the AQUAsition program, version 2.2.1.7, as previously de-
scribed.35 Briefly, a tumor specific mask was generated to
distinguish the NSCLC cells from normal tissue by thresh-
olding the pan-cytokeratin images. Thresholding created a
binary mask that identified the presence or absence of tumor
cells by the presence of a pixel that was “on” or “off,”
respectively. Thresholding levels were verified and adjusted
if necessary, by spot-checking a small sample of images to
determine an optimal threshold value. All images were then
processed using this optimal threshold value, and all subse-
quent image manipulations involved only image information
from the masked area. The target CXCR4 signal in the
masked area was tabulated and used to generate tumor-
specific AQUA scores, which reflect the average signal
intensity per tumor area. Images were validated according
to the following: (1) more than 10% of the tissue area is
pan-cytokeratin positive, (2) more than 50% of the image
was usable (i.e., not compromised due to overlapping or
out of focus tissue). Unusable areas within each image
were manually cropped so that they were excluded from
the final analysis.
Statistical Analysis
Descriptive statistics compared the frequencies of
measured patient and pathological features between the
full, TMA, and non-TMA cohorts, as well as the male and
female expression groups within the TMA cohort. A cut-
point to create two groups from the maximum CXCR4
expression levels was found using a method based on the
log-rank test statistic.36 The relationships between CXCR4
scores and clinicopathological variables of interest were
evaluated using Fisher’s exact test with mid-p adjustment
for categorical data and two-sample Student t test for the
age variable. Equivalence between the TMA and non-TMA
groups was evaluated using a multinomial goodness-of-fit
approach for the categorical variables and a two-sample t
test for the continuous variable. Survival analyses assessed
the equivalence of the survival experiences between the
TMA and non-TMA groups,37 tested the observed differ-
ences in the survival experiences of low and high expres-
sors, and evaluated clinicopathological features in Cox
proportional hazards (PH) regression models. PH assump-
tions were assessed using scaled Schoenfeld residual plots
and trend test statistics.38 Validation of the final Cox PH
regression model was based on the c (concordance) index
derived from Somers’ Dxy rank correlation, using 200
bootstrap samples.39,40 All analyses were conducted with
SAS/STAT software (Version 9.2) SAS System for Unix41
and R software (version 2.11).42
RESULTS
Patient Characteristics
Description of Full Clinical Cohort
Between January 2003 and December 2006, 832 pa-
tients were diagnosed with stage IV NSCLC at the Tom
Baker Cancer Centre. Patient demographics and clinical char-
acteristics for all patients (full cohort) included in the clinical
analysis are summarized in column 2 of Table 1. Median age
was 69 years, 51.4% were male, 85.8% were ex- or current
smokers, 7.8% were of Southeast Asian origin, and 65.9%
had M1b disease. In terms of tumor histology, 43.8% were
adenocarcinomas, 18.9% squamous cell carcinomas, 32.3%
NOS, and 5.1% were other histology (large cell carcinoma,
bronchioloalveolar carcinoma, and adenosqamous carci-
noma). Treatment varied widely and was largely heteroge-
neous in the cohort: 21.0% of patients received no treatment,
7.0% chemotherapy alone, 55.7% palliative radiotherapy
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alone, and 16.4% received both chemotherapy and pallia-
tive radiotherapy at some point during the course of their
disease (data not shown). In addition, 8.3% of patients
received treatment with epidermal growth factor receptor
kinase inhibitors (includes both alone and with palliative
radiotherapy).
Description of Cohort in TMA
Of the 832 stage IV patients included in the clinical
analysis, 290 patients had diagnostic or resected tissue spec-
imens available (not including 21 patients who had tissue
biopsies in locations other than Calgary). The remaining 521
patients did not have a tissue diagnosis (n  107), had tissue
biopsies unavailable for retrieval (n 12), or were diagnosed
based on cytological tissue specimens (fine needle aspirate,
bronchial washing, bronchoalveolar lavage wash, thoracente-
sis, or sputum sample) (n 402), which were not suitable for
inclusion into the TMAs. Ultimately, only 170 patients had
tissue samples deemed of sufficient quality for TMA incor-
poration and analysis. Seven of these patients had two sepa-
rate biopsy samples included into TMAs and AQUA scores,
which were averaged before analysis. The 177 tumor speci-
mens consisted of tissue obtained from primary tumor (n 
101) or metastatic deposits (n  76) (including distant me-
tastases and lymph nodes).
The demographics and clinical characteristics of the
170 patients included in the molecular analysis are summa-
rized in column 3 of Table 1. Median age was 67 years,
50.6% were male, 82.4% were current or ex-smokers, 9.4%
were of Southeast Asian ethnicity, 71.2% presented with M1b
disease, 5.3% received only chemotherapy, 62.4% only ra-
diotherapy, 19.4% both therapies, and 12.9% no therapy (data
not shown). In addition, 53.5% of the patients had adenocar-
cinoma tumor histology, 28.8% squamous cell carcinoma,
and only 12.4% of patients had tumor histology not otherwise
specified (NOS), which was significantly less than in the
clinical cohort as a whole.
Patients with tissue suitable for inclusion into TMAs
had similar characteristics to the stage IV cohort of patients
without available tissue. Table 1 (columns 4–7) demonstrates
that most predictor variables were equivalent using a strict
tolerance value (10%), when the TMA sample was compared
with the non-TMA reference group with two exceptions: the
TMA group included higher proportions of patients who
received radiotherapy, more patients diagnosed with adeno-
carcinoma or squamous cell carcinoma, and a corresponding
lower proportion of patients whose diagnoses were NOS. The
non-TMA cohort (n  662) had a median overall survival
(MOS) of 3.75 months (95% confidence interval [CI] 
3.29–4.37) versus 5.22 months (95% CI  3.71–6.05) for
those patients in the TMA cohort (n  170). Comparison of
the Kaplan-Meier survival curves of the two cohorts using a
log-rank test of equivalence showed that the curves never
separated more than 10% over the study duration, which was
within our strict equivalence interval (Figure 1). Thus, the
overall unadjusted survival of the 170 patients whose tumors
were suitable for TMA inclusion was very similar to those
whose tumors were not suitable for TMA inclusion, suggest-
ing that they are reasonably representative of stage IV pa-
tients as a whole.
CXCR4 Expression by Quantitative Fluorescent
IHC in Stage IV NSCLC Patient Specimens
Quantitative fluorescent IHC was successfully com-
pleted for all patients included in the TMAs. Automated
quantitative analysis (AQUA) was performed on the images
TABLE 1. Demographic Details of Patients with Stage IV
NSCLC
Full Cohort
(n  832) n (%)
TA Cohort
(n  170) n (%)
Non-TA Cohort
(n  662) n (%)
Gender
Female 404 (48.6) 84 (49.4) 320 (48.3)
Male 428 (51.4) 86 (50.6) 342 (51.7)
Histology
Adenocarcinoma 364 (43.8) 91 (53.5) 273 (41.2)
Squamous cell 157 (18.9) 49 (28.8) 108 (16.3)
Large cell 24 (2.9) 3 (1.8) 21 (3.2)
BAC 12 (1.4) 5 (2.9) 7 (1.1)
Adenosquamous 6 (0.7) 1 (0.6) 5 (0.8)
NOS 269 (32.3) 21 (12.4) 248 (37.5)
Radiotherapy
No 233 (28.0) 31 (18.2) 202 (30.5)
Yes 599 (72.0) 139 (81.8) 460 (69.5)
Systemic therapy
No 638 (76.7) 128 (75.3) 510 (77.0)
Yes 194 (23.3) 42 (24.7) 152 (23.0)
No. of lines if yes
1 116 (59.8) 26 (61.9) 90 (59.2)
2 42 (21.7) 5 (11.9) 37 (24.3)
3 24 (12.4) 8 (19.1) 16 (10.5)
4 10 (5.2) 3 (7.1) 7 (4.6)
6 2 (1.0) 0 (0.0) 2 (1.3)
EGFR TKI therapy
No 763 (91.7) 154 (90.6) 609 (92.0)
Yes 69 (8.3) 16 (9.4) 53 (8.0)
Distant 548 (65.9) 121 (71.2) 427 (64.5)
Local 284 (34.1) 49 (28.8) 235 (35.5)
Smoking status
Current 268 (32.2) 53 (31.2) 215 (32.5)
Ex 446 (53.6) 87 (51.2) 359 (54.5)
Never 86 (10.3) 23 (13.5) 63 (9.5)
Unknown 32 (3.9) 7 (4.1) 25 (3.8)
Origin
North American 609 (73.2) 124 (72.9) 485 (73.3)
Southeast Asian 65 (7.8) 16 (9.4) 49 (7.4)
Other 158 (19.0) 30 (17.6) 128 (19.3)
Region
Rural 105 (12.6) 26 (15.3) 79 (11.9)
Urban 727 (87.4) 144 (84.7) 583 (88.1)
Age
Mean (SD) 68.1 (11.2) 66.4 (10.7) 68.5 (11.2)
Median 69 67 69
Range 32–96 32–88 39–96
Values are given as N (%).
NSCLC, non-small cell lung cancer; TA, tissue array; BAC, bronchioloalveolar
carcinoma; NOS, not otherwise specified.
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created after tissue CXCR4 staining, and an AQUA score
representing the tumor-specific, non-nuclear CXCR4 receptor
expression for each patient tissue specimen was obtained.
The value of AQUA measurements using “keratin masking”
enables accurate determination of CXCR4 expression within
only the epithelial cells of the cancer. To verify the specificity
of the UMB2 rabbit monoclonal antibody used to detect
CXCR4, Hela cells were used as positive controls while
normal human tonsil tissue was also used as both a positive
and negative control. Hela cells showed strong CXCR4
staining. In the tonsil, germinal center cells expressed high
levels of CXCR4, mantle zone cells expressed moderate
levels of CXCR4, and cells of the surrounding lymphoid
tissue expressed low levels of CXCR4. In the absence of the
CXCR4 antibody, no specific staining in the tonsil was
observed (Figure 2A).
Normal lung displayed CXCR4 staining only in endo-
thelial cells of the alveolar capillaries. There was no staining
in the lung epithelial cells. The lung tumors displayed a range
of CXCR4 expression with some cases devoid of significant
expression and others displaying marked cytoplasmic expres-
sion (Figure 2B). In all cases, there seemed to be strong
CXCR4 expression in the associated endothelial cells of the
capillaries (Figure 2B, middle panel). The cytoplasmic ex-
pression pattern, the lack of nuclear expression, and the
CXCR4 expression in the endothelial cells of the capillaries
are all consistent with the original characterization of the
anti-CXCR4 rabbit monoclonal antibody used in this study.34
The mean AQUA score for the 170 patients was 2512.44 (SD
1371.74). When plotted on a frequency histogram, the distri-
FIGURE 1. Kaplan-Meier survival curve comparing the overall
survival of the tissue array (TA) and non-TA cohorts. The curves
never deviate more than 10% over the study duration.
FIGURE 2. CXCR4 immunohisto-
chemistry (IHC) staining. A, CXCR4
staining in positive control Hela cells
and tonsil tissue with and without
the primary antibody. B, Interroga-
tion of non-small cell lung cancer
(NSCLC) samples on tissue microar-
ray (TMA) for CXCR4 expression by
IHC using the HistoRx/AQUA plat-
form. CXCR4 is expressed in normal
lung tissue only in the endothelial
cells and is frequently expressed in
NSCLC with a cytomembranous
distribution.
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bution of CXCR4 AQUA scores was right skewed and ranged
from a minimum of 536.00 to a maximum of 8317.73
(median 2227.31).
To divide the patients into high and low CXCR4
expressing groups, an AQUA score cut-point of 3371.00 was
determined using a log-rank test statistic method and con-
firmed graphically with plots of martingale residuals from a
null model against the AQUA score.38 Twenty-nine (17.1%)
patients had an AQUA score more than 3371.00 and thus
were considered high expressors; the remaining 141 patients
were considered to have low CXCR4 expression. Patient
demographics of the two CXCR4 expression groups by gen-
der are summarized in Table 2.
Association of CXCR4 Expression and Overall
Survival
Overall survival was the main outcome of interest, with
only one patient censored at the study end date, June 8, 2010.
Potential confounding factors were forced into all Cox PH
regression models regardless of statistical significance; these
included all treatment variables (systemic therapy, radiother-
apy, and epidermal growth factor receptor tyrosine kinase
inhibitor [EGFR TKI] treatment), age (years), gender, smok-
ing status, histology, TMA batch, and location of metastases
(thoracic or distant). Initial multivariable models assessed the
importance of CXCR4 AQUA score status (high versus low)
jointly with region of residence, tissue biopsy site, race, and
race-smoking status interactions. Reduced models (dropped
race, race-smoking status interactions, and tissue biopsy site),
based on likelihood ratio statistics (p  0.05), next assessed
CXCR4 AQUA score status interactions with radiotherapy,
histology, systemic therapy, metastases location, gender, and
EGFR TKI treatment.
Two factors associated with overall survival in the final
Cox PH regression model included (1) EGFR TKI treatment
and (2) CXCR4 AQUA score status-gender interaction. Re-
ceiving EGFR TKI treatment reduced the risk of dying by
0.48 (95% CI  0.22–1.01), which was marginally above the
statistical significance value of 0.05. Of greater interest is the
influence of gender on outcome in the CXCR4 high expres-
sors. Women with high CXCR4 expression had more than
TABLE 2. Demographic Details of Patients with High and Low CXCR4 Expression, Stratified by Gender
Females (n  84) Males (n  86)
Low (n  74) High (n  10) pa Low (n  67) High (n  19) pa
Histology
Adenocarcinoma 45 (60.8) 4 (40) 0.37 38 (56.7) 4 (21.1) 0.0074
Squamous cell 16 (21.6) 5 (50) 15 (22.4) 13 (68.4)
Large cell 1 (1.4) 0 (0) 2 (2.9) 0 (0)
BAC 3 (4.1) 0 (0) 2 (2.9) 0 (0)
Adenosquamous 0 (0) 0 (0) 1 (1.5) 0 (0)
NOS 9 (12.2) 1 (10) 9 (13.4) 2 (10.5)
Radiotherapy
No 10 (13.5) 3 (30) 0.11 15 (22.4) 3 (15.8) 0.64
Yes 64 (86.5) 7 (70) 52 (77.6) 16 (84.2)
Systemic therapy
No 54 (72.9) 9 (90) 0.35 50 (74.6) 15 (78.9) 0.77
Yes 20 (27) 1 (10) 17 (25.4) 4 (21)
Metastases
Distant 52 (70.3) 7 (70) 0.86 49 (73.1) 13 (68.4) 0.67
Local 22 (29.7) 3 (30) 18 (26.9) 6 (31.6)
Smoker
Current 19 (2.7) 4 (40) 0.23 21 (31.3) 9 (47.4) 0.60
Ex 36 (48.7) 5 (50) 37 (55.2) 9 (47.4)
Never 16 (21.6) 0 (0) 6 (8.9) 1 (5.3)
Unknown 3 (4.1) 1 (10) 3 (4.5) 0 (0)
Origin
North American 51 (68.9) 10 (100) 0.44 45 (67.2) 18 (94.7) 0.22
Southeast Asian 8 (10.8) 0 (0) 7 (10.4) 1 (5.3)
Other 15 (20.3) 0 (0) 15 (22.4) 0 (0)
Age
Mean (SD) 66.6 (11.9) 71.6 (10.3) 0.18 65.7 (9.9) 64.9 (8.4) 0.73
Median 68.5 75.5 65 67
Range 32–88 48–83 43–85 46–76
Values are given as N (%).
a Based on Fisher exact test with mid-p adjustment for categorical data and two-sample student’s t test with unequal variances for age variable.
BAC, bronchioloalveolar carcinoma; NOS, not otherwise specified.
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fivefold increased risk of death relative to women with low
expression levels (hazard ratio [HR]  5.36; 95% CI 
2.44–11.79), whereas men were about twice as likely to die
regardless of expression level (high expression levels: HR 
1.77, 95% CI  0.98–3.22; low expression levels: HR 
2.07, 95% CI  1.42–3.02).
Kaplan-Meier survival curves were also generated
comparing the overall survival between the high and low
CXCR4 expressing groups (Figure 3A). The high expression
group (AQUA score 3371.00) had a significantly poorer
survival experience compared with the low expression group
(p  0.047 from exact log-rank test statistic), with a MOS of
2.7 months (95% CI 1.9–5.2) compared with a MOS of 5.6
months (95% CI  4.2–6.9). The gender-CXCR4 interaction
found in the Cox PH model suggests that this difference in
outcome is driven primarily by the female patients with high
CXCR4 expression. Kaplan-Meier survival curves comparing
the overall survival of the high versus low CXCR4 expressors
in females and males can be seen in Figures 3B, C, respec-
tively. In females, the patients with high CXCR4 expression
have a significantly decreased overall survival when com-
pared with those with low CXCR4 expression (p  0.006)
with a MOS of 1.6 months (95% CI  0.5–2.6) for high
expressors versus 6.4 months (95% CI 5.4–9.8) for the low
expressors. In males, no significant difference can be seen in
survival between the two expression groups (p  0.65) with
a MOS of 3.4 months (95% CI  2.6–6.0) for the low
expressors and 3.7 months (95% CI  1.9–8.8) for the high
expressors. Median overall survival and HRs for the high and
low expression groups separated by gender are summarized
in Figure 3D.
Because systemic therapy and radiotherapy failed to
meet the PH assumption, they were incorporated as stratify-
ing factors into the model. Diagnostic plots assessed the
functional form of age and the presence of influential or
outlying observations. Internal model validation was carried
out using 200 bootstrap samples. It revealed slight overfitting
(over-estimation of the regression coefficients) by up to 38%
FIGURE 3. Kaplan-Meier survival curves comparing the overall survival between the high and low CXCR4 expression groups:
(A) whole tissue microarray (TMA) cohort, (B) females, (C) males. (D) Summary table of the median overall survival and HRs
for high and low expressing groups stratified on gender. High expressing females have a 5.4 times increased risk of death
compared with the low expressors and a median overall survival (MOS) of only 1.6 months.
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but still acceptable discrimination ability (c-index or area
under the receiver operating curve was 0.71).40
Association of CXCR4 Expression and Histology
The relationship between CXCR4 AQUA score status
and histology type was investigated to determine whether this
could be impacting the significant gender-CXCR4 AQUA
score status interaction. It should be noted that histology
(overall or any subtype) was not significant in the final Cox
PH regression model, which did adjust for gender, nor was
the three-way interaction between histology, gender, and
CXCR4 (CXCR4 score modeled as continuous; results not
shown). There was no difference in the distribution of his-
tology subtypes between males and females (p  0.63, result
not shown), but there was between the high and the low
CXCR4 expression groups (p  0.00036, result not shown).
In the high CXCR4 expression group, there was a smaller
proportion of individuals with adenocarcinomas and a higher
proportion with squamous cell carcinomas. When these dis-
tributions are examined within gender strata, it becomes
apparent that these differences are much more pronounced
among the males (p  0.0074) than the females (p  0.37).
Clearly, the small number of men and women in the high
CXCR4 groups limits further assessment; however, the ear-
lier analyses show that histology differences are not solely
driving the observed gender-CXCR4 group interaction.
DISCUSSION
Evidence increasingly suggests that the CXCR4/SDF-1
chemokine axis is important in the development and progres-
sion of several tumor types, particularly breast cancer. In
NSCLC, the evidence is more controversial: a number of
studies have examined CXCR4 expression and association
with outcome in early-stage NSCLC, but there are little data
on CXCR4 in advanced disease. Our results confirm that
CXCR4 is expressed by the malignant component of a tumor
mass in almost all cases of stage IV NSCLC and that its
expression can be described as being mainly cytomembra-
nous with little expression in the nucleus. These findings
support CXCR4 as a potential therapeutic target for NSCLC.
Several anti-CXCR4 compounds have been developed for
treating human immunodeficiency virus, thus allowing rapid
transition into clinical trials.
In addition, our results also suggest that CXCR4 ex-
pression appears to be a prognostic biomarker in stage IV
NSCLC. We report that in our cohort of patients, high
expression of the CXCR4 receptor as assessed by quantitative
IHC conferred a significantly worse prognosis in the stage IV
NSCLC patients studied. Moreover, it appears that this sur-
vival difference is a gender-dependent effect, because only
the females are negatively affected by high CXCR4 receptor
expression with a five times greater risk of death compared
with those with low expression. In contrast, no significant
difference was seen in overall survival between the high and
low expressing groups in the male population.
This gender difference in the correlation of CXCR4
receptor expression with clinical outcome is an intriguing
finding and has not been previously reported. Our study did
not provide a clear explanation for this phenomenon; how-
ever, a gender-based molecular-dependent difference in out-
come in NSCLC is not improbable. It is generally accepted
that there are gender-based outcome differences in NSCLC in
early resectable disease43–45 and in more advanced dis-
ease.46–49 More recently, clinical experience,3,50,51 and now
molecular analyses,52,53 has shown that responses to the
EGFR TKIs and the activating mutations underpinning such
responses are more common in females, although the etiology
of this difference is unexplained. However, unlike our study,
most of these reports associate female gender with improved
outcomes and longer survival.
Interestingly, there have been recent reports of a posi-
tive regulatory loop between the CXCR4/SDF-1 chemokine
axis and estrogen receptor (ER) signaling pathways, which
influence both ER- and CXCR4-dependent gene expression
and ultimately tumor cell growth in vitro.54 Some studies
have demonstrated that a significant proportion of NSCLC
tumors express ERs55,56 and that there may be a gender-
dependent difference in ER expression.57,58 Despite this,
there does not seem to be a consensus on whether ER
expression has any bearing on clinical outcome in
NSCLC.59,60 It can be postulated that if ERs were also present
in tumors that express high levels of CXCR4, a significant
increase in both CXCR4- and ER-dependent gene transcrip-
tion (including SDF-1) could occur specifically in females
due to the positive regulatory loop between the two receptors,
accelerating progression and metastasis and resulting in the
subsequent decrease in survival. If that is the case, then
factors influencing estrogen concentration such as meno-
pausal status or obesity (factors not explored in this retro-
spective analysis) may influence survival of female patients
with NSCLC.
Our study has several attributes that strengthen its
validity. A sample size of 170 interrogatable specimens
compares favorably with other studies of molecular analysis
in stage IV disease.61,62 A low proportion of analyzable
samples is a conspicuous feature of many studies of advanced
NSCLC (even those based on clinical trials that include
molecular correlative studies in their design) and highlights
one of the challenges inherent in any translational work in
metastatic lung cancer. We were also able to demonstrate that
our interrogated TMA population is representative of all stage
IV patients in our database. Furthermore, by making use of
AQUA technology and a better quality antibody (UMB-2),
we were able to analyze CXCR4 expression quantitatively
using IHC in all specimens studied and determine more
precisely the specific localization of the receptor.
In previous studies assessing the expression of CXCR4
in lung tumors, localization of the receptor was generally
seen in both the nucleus and cytoplasm/membrane of NSCLC
tumor cells.29–32 However, there has been a great deal of
inconsistency in these studies in terms of the associations
found between the expression and localization of CXCR4 and
clinical outcome. Nuclear CXCR4 expression has been asso-
ciated with a better prognosis,29 has had no effect on out-
come,31 and has also been associated with lymph node me-
tastasis.32 On the other hand, total mRNA expression has
been associated with a better clinical outcome,30 whereas
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cytomembraneous CXCR4 expression has been shown to
confer a worse prognosis.31
Much of this inconsistency may be due to the use of
undercharacterized mouse monoclonal antibodies in these
studies, which have not been thoroughly tested for specificity
in formalin-fixed paraffin-embedded tissues,34 as well as the
potential subjectivity in the analysis of semiquantitative IHC
staining. Our findings demonstrate that CXCR4 has a pre-
dominantly cytomembraneous expression in NSCLC tumor
cells and as CXCR4 is known to be a surface receptor, we
would expect a greater proportion of the expression seen to be
cytomembranous. The UMB-2 rabbit monoclonal antibody
used was extensively characterized and shown to accurately
detect membrane receptors while showing little staining in
the cell nucleus,34 which is more compatible with the known
function and signaling of this receptor.63
The possible involvement of the CXCR4/SDF-1 axis in
cancer is an attractive pathway to investigate because it helps
explain the Paget “seed and soil” phenomenon associated
with metastasis. The two key components of metastasis—
acquisition of the capability to break away from the primary
tumor to become blood or lymph borne and the subsequent
ability to home in on its metastatic destination—can both be
influenced by the CXCR4/SDF-1 axis. Increased activation of
this pathway can confer on the malignant cell a greater ability
to migrate and invade,17,64 whereas the constitutive release by
stromal cells from common sites of metastasis such as bone
marrow, lung, and liver can guide the circulating cell to home
in on its metastatic destination.65 The role played by the
CXCR4/SDF-1 axis in leukocyte trafficking and homing of
stem cells66,67 is likely analogous to organ selective metasta-
sis of cancer stem cells.68 In this model, metastatic potential
of a cell will be determined by surface CXCR4 expression,
whereas its destiny will be influenced by local SDF-1 secre-
tion at distal sites. As such, the CXCR4/SDF-1 axis can help
explain the “nature” underlying metastatic tendency (CXCR4
expression), as well as the “nurture” of that tendency (SDF-1
secretion at metastatic sites).
In summary, we report that CXCR4 is commonly
expressed in stage IV NSCLC and is therefore a potential
therapeutic target in this disease. In addition, we suggest that
CXCR4 may also have a gender-dependent prognostic sig-
nificance because women whose tumors overexpress this
receptor seem to have a significantly worse survival. Further
studies are needed to validate these findings in other sample
series and to shed light on the possible association between
CXCR4 and ER function in NSCLC.
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